What is the study of Mampuya et al. (2013) about?
Mampuya et al. (2013) conducted a retrospective cohort study of 1,605 patient records to evaluate the efficacy of intermittent statin dosing compared to daily dosing and statin discontinuation in patients with confirmed intolerance. In this population, 63.2% of patients tolerated daily statin dosing, 9.3% tolerated intermittent dosing, and 27.5% discontinued statins. Intermittent dosing regimens ranged from once weekly to six days per week. Rosuvastatin was the most commonly used statin in the intermittent group, accounting for 75.2% of statin prescriptions. Both daily and intermittent dosing led to a significantly greater reduction in the surrogate endpoints of TC and LDL-C compared to statin discontinuation, with greater benefit from daily dosing. About 70% of studied patients were taking concomitant lipid-lowering prescription medications and supplements.